Moreover, empagliflozin, a selective inhibitor of SGLT2 by binding directly to SGLT2, has been reported to exert cardioprotective effects in several cardiovascular diseases, including heart failure and diabetic cardiomyopathy [[33], [34], [35]]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.